170 related articles for article (PubMed ID: 38428407)
1. GBA3 promotes fatty acid oxidation and alleviates non-alcoholic fatty liver by increasing CPT2 transcription.
Li J; Ni Y; Zhang Y; Liu H
Aging (Albany NY); 2024 Feb; 16(5):4591-4608. PubMed ID: 38428407
[TBL] [Abstract][Full Text] [Related]
2. E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
González-Romero F; Mestre D; Aurrekoetxea I; O'Rourke CJ; Andersen JB; Woodhoo A; Tamayo-Caro M; Varela-Rey M; Palomo-Irigoyen M; Gómez-Santos B; de Urturi DS; Núñez-García M; García-Rodríguez JL; Fernández-Ares L; Buqué X; Iglesias-Ara A; Bernales I; De Juan VG; Delgado TC; Goikoetxea-Usandizaga N; Lee R; Bhanot S; Delgado I; Perugorria MJ; Errazti G; Mosteiro L; Gaztambide S; Martinez de la Piscina I; Iruzubieta P; Crespo J; Banales JM; Martínez-Chantar ML; Castaño L; Zubiaga AM; Aspichueta P
Cancer Res; 2021 Jun; 81(11):2874-2887. PubMed ID: 33771899
[TBL] [Abstract][Full Text] [Related]
3. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
[TBL] [Abstract][Full Text] [Related]
4. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
Ganji SH; Kashyap ML; Kamanna VS
Metabolism; 2015 Sep; 64(9):982-90. PubMed ID: 26024755
[TBL] [Abstract][Full Text] [Related]
5. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
6. Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease.
Ji PX; Chen YX; Ni XX; Miao Q; Hua J
J Gastroenterol Hepatol; 2024 Feb; 39(2):369-380. PubMed ID: 38012119
[TBL] [Abstract][Full Text] [Related]
7. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD.
Weber M; Mera P; Casas J; Salvador J; Rodríguez A; Alonso S; Sebastián D; Soler-Vázquez MC; Montironi C; Recalde S; Fucho R; Calderón-Domínguez M; Mir JF; Bartrons R; Escola-Gil JC; Sánchez-Infantes D; Zorzano A; Llorente-Cortes V; Casals N; Valentí V; Frühbeck G; Herrero L; Serra D
FASEB J; 2020 Sep; 34(9):11816-11837. PubMed ID: 32666604
[TBL] [Abstract][Full Text] [Related]
8. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
[TBL] [Abstract][Full Text] [Related]
9. Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation.
Weng SW; Wu JC; Shen FC; Chang YH; Su YJ; Lian WS; Tai MH; Su CH; Chuang JH; Lin TK; Liou CW; Chu TH; Kao YH; Wang FS; Wang PW
Diabetologia; 2023 May; 66(5):913-930. PubMed ID: 36692509
[TBL] [Abstract][Full Text] [Related]
10. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
11. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
[TBL] [Abstract][Full Text] [Related]
12. Corn peptides improved obesity-induced non-alcoholic fatty liver disease through relieving lipid metabolism, insulin resistance and oxidative stress.
Wei K; Wei Y; Xu W; Lu F; Ma H
Food Funct; 2022 May; 13(10):5782-5793. PubMed ID: 35537139
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
[TBL] [Abstract][Full Text] [Related]
15. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
16. Hesperetin ameliorates hepatic oxidative stress and inflammation
Li J; Wang T; Liu P; Yang F; Wang X; Zheng W; Sun W
Food Funct; 2021 May; 12(9):3898-3918. PubMed ID: 33977953
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Fatty Acid Translocase (FAT/CD36) Palmitoylation Enhances Hepatic Fatty Acid β-Oxidation by Increasing Its Localization to Mitochondria and Interaction with Long-Chain Acyl-CoA Synthetase 1.
Zeng S; Wu F; Chen M; Li Y; You M; Zhang Y; Yang P; Wei L; Ruan XZ; Zhao L; Chen Y
Antioxid Redox Signal; 2022 Jun; 36(16-18):1081-1100. PubMed ID: 35044230
[No Abstract] [Full Text] [Related]
18. Exploratory Data Analysis of Cell and Mitochondrial High-Fat, High-Sugar Toxicity on Human HepG2 Cells.
Amorim R; Simões ICM; Veloso C; Carvalho A; Simões RF; Pereira FB; Thiel T; Normann A; Morais C; Jurado AS; Wieckowski MR; Teixeira J; Oliveira PJ
Nutrients; 2021 May; 13(5):. PubMed ID: 34069635
[TBL] [Abstract][Full Text] [Related]
19. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
[TBL] [Abstract][Full Text] [Related]
20. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
